Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects.

ABSTRACT:

Aims

Since the launch of semaglutide for weight loss (Wegovy®, SEMA-WL) in late 2022, there has been a huge increase in new users of SEMA-WL. We explored characteristics, treatment expectations and experienced effectiveness and side effects among Danish adults using SEMA-WL.

Materials and methods

A questionnaire-based survey was conducted from September to December 2023 across 29 Danish community pharmacies. During a 10-day period, pharmacies invited consecutive individuals aged ≥18 years redeeming a prescription on SEMA-WL to complete an electronic questionnaire.

Results

A total of 1013 individuals were invited to study participation of which 55% (n = 559) accepted. Users of SEMA-WL were primarily female (78%, n = 434) and middle-aged adults (36-65 years; 76%, n = 42

SUBMITTER: Sorensen MS 

PROVIDER: S-EPMC11885084 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature